Tag: Trodusquemine

Despite undergoing early-phase clinical trials in the early 2000s, trodusquemine is an investigational drug that is **not approved by the FDA and cannot be purchased for human consumption in the USA**. Its development was halted due to financial difficulties, and though research continues under new sponsors, it remains a substance strictly for research purposes.

First isolated from the liver extracts of the spiny dogfish shark, *Squalus acanthias*, in the early 2000s, trodusquemine is a naturally occurring aminosterol investigated for its therapeutic potential in metabolic and neurodegenerative diseases. What are the natural sources of trodusquemine and how has this unique compound made the journey from a marine organism to a subject of modern medical research?

Despite completing early-stage clinical trials for conditions like diabetes and obesity, the experimental drug trodusquemine remains unavailable for human medical use. Its availability is restricted exclusively to laboratory research purposes, preventing its acquisition for personal health treatment.

Trodusquemine is an investigational drug not approved for human use by the FDA, meaning it has no standard consumer price [1.3.1]. The key question remains: how much does trodusquemine cost in the USA for research purposes?

In pre-clinical studies, a single dose of trodusquemine led to a 20% reduction in body weight in mice on a high-fat diet [1.3.9]. This article explores the question: What are the benefits of trodusquemine, an investigational drug with a unique mechanism of action?

As of late 2025, Trodusquemine is not approved by the U.S. Food and Drug Administration (FDA) for human use and is not commercially available in the United States. The compound remains an investigational drug, available only for research purposes through commercial suppliers.

Over the past two decades, the compound trodusquemine (MSI-1436) has been passed between multiple companies, each exploring its potential for different conditions from obesity to muscular dystrophy. The tumultuous history of who is developing trodusquemine highlights the high-stakes and often volatile nature of pharmacological research and development.

Trodusquemine (also known as MSI-1436) can be purchased from commercial suppliers for research purposes, but it is not available for human use in the USA [1.3.1]. This investigational drug has not been approved by any regulatory agency for public sale or prescription [1.2.2].

According to a groundbreaking 2017 study, a single dose of trodusquemine appeared to completely reverse the effects of atherosclerosis in preclinical mouse models. This remarkable finding ignited interest in a key question for cardiovascular health: **Can trodusquemine reverse atherosclerosis** in humans?

Initial Phase I clinical trials for Trodusquemine showed good tolerability and promising results for metabolic conditions, but several planned Phase II trials were abruptly halted due to the original developer's financial collapse. This financial failure, not safety or efficacy issues, largely explains what happened to Trodusquemine's progress as a potential commercial drug.